Citius Pharmaceuticals, Inc. (CTXR) Return on equity 2017–2022
Citius Pharmaceuticals, Inc. (CTXR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-32.7%FY2022 · since FY2017: -47.3% → -32.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -32.7% | -15.3 pp |
| FY2021 | -17.4% | +34.7 pp |
| FY2020 | -52.1% | +5.2 pp |
| FY2019 | -57.3% | -16.4 pp |
| FY2018 | -40.9% | +6.4 pp |
| FY2017 | -47.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CTXR financial trends
CTXR RevenueCTXR Net incomeCTXR Net marginCTXR Gross profitCTXR Gross marginCTXR Operating incomeCTXR Operating marginCTXR Operating cash flowCTXR Free cash flowCTXR Capital expendituresCTXR Stock buybacksCTXR Dividends paidCTXR Total assetsCTXR Total liabilitiesCTXR Shareholders’ equityCTXR overview →